Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Malaga – page 25

1 063 clinical trials in Malaga, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Malaga at a glance
1 063
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 063 trials in Malaga

Open in trial search

Squamous cell carcinoma of head and neck

Recruiting

Study of Cetuximab and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Pembrolizumab Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Grupo Espanol De Tratamiento De Tumores De Cabeza Y Cuello

Hepatocellular carcinoma+1

Recruiting

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Glucose tolerance impaired+1

Recruiting

Study of pioglitazone and metformin combination treatment for patients with Metabolic Associated Fatty Liver Disease and prediabetes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pioglitazone
  • Sponsor:Consorcio Centro De Investigacion Biomedica En Red

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Patients Hospitalized with Heart Failure

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Colorado Prevention Center

Type IIa hyperlipidaemia

Recruiting

Study on the Safety and Effectiveness of Inclisiran for Children Aged 6 to Under 12 with Familial Hypercholesterolemia

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer

Recruiting

Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MPS-102
  • Sponsor:Fondazione Ricerca Traslazionale

Systemic scleroderma

Recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Acute respiratory failure

Recruiting

Study on the Effects of Dexamethasone in Adults with Acute Respiratory Failure Due to Infections, Including COVID-19

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Consorcio Centro De Investigacion Biomedica En Red

Extra-osseous Ewing's sarcoma+5

Recruiting

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:The University Of Birmingham

Acute myeloid leukaemia

Recruiting

Study on Teicoplanin for Preventing Infections in Children with Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Teicoplanin
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Juvenile idiopathic arthritis

Recruiting

Study of Sarilumab for Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Sarilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neoplasm malignant

Recruiting

Study of ART6043, Olaparib, and Niraparib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ART6043
  • Sponsor:Artios Pharma Limited

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Malaga

What the registry says about research in the country

01 Autoimmune Conditions

Research focusing on innovative treatments for cutaneous lupus erythematosus and myasthenia gravis, evaluating new therapeutic approaches to improve patient outcomes.

  • Lupus skin manifestations
  • Neuromuscular disorders
  • Chronic urticaria management

Studies aim to assess novel therapies' effectiveness in reducing disease activity and improving daily living activities.

02 Infectious Diseases

Innovative vaccine development studies targeting COVID-19, cytomegalovirus, and respiratory syncytial virus, focusing on prevention and immune response.

  • Viral infections
  • Vaccine combinations
  • Pediatric prevention

Research emphasizes safety and immunogenicity in various population groups.

03 Oncology

Advanced studies in bladder cancer, colorectal cancer, and gastric cancer, evaluating targeted therapies and combination treatments.

  • Non-muscle invasive treatments
  • Metastatic disease management
  • Immunotherapy approaches

Trials focus on improving survival rates and treatment responses in various cancer types.

04 Respiratory Medicine

Research examining new treatments for chronic rhinosinusitis and COPD, with emphasis on symptom management and exacerbation prevention.

  • Airway inflammation
  • Pulmonary function
  • Quality of life measures

Studies evaluate novel therapeutic approaches for chronic respiratory conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.